Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE Study)

Trial Profile

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE Study)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fidaxomicin (Primary)
  • Indications Clostridium difficile infections
  • Focus Therapeutic Use
  • Acronyms DAFNE
  • Sponsors Astellas Pharma

Most Recent Events

  • 01 Jun 2021 Results (n=294) assessing the characteristics, management and outcomes of hospitalised patients with clostridium difficile infection who were treated with fidaxomicin and also describes the management of patients with CDI who did not receive fidaxomicin, published in the Journal of International Medical Research.
  • 11 Oct 2017 Status changed from active, no longer recruiting to completed.
  • 26 Sep 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top